Patient and Treatment Characteristics for Crohnʼs Patients Initiating Therapy With Ustekinumab

Introduction: Ustekinumab was approved for the treatment of Crohn's Disease (CD) in September 2016. The purpose of this analysis was to describe patient demographics and treatment characteristics of patients initiating ustekinumab for CD. Methods: The analytic cohort was drawn from an immunology subset of Symphony Health Solutions data (10/1/2012 through 3/31/2017). Patients were included in the analysis if they had ≥ 2 CD diagnoses (ICD-9:...